To Protect Themselves From Breast Cancer Recurrence (NAPSA)—Postmenopausal breast cancer patients treated with five years of tamoxifen immediately following surgery may reduce their risk of their cancer returning by starting treatment a =" = with Femara (letrozole tablets), according to information published in a recent issue of the Journal of Clinical Oncology. Results from an exploratory analysis found that women who started Femara from less than one to seven years after finishing tamoxifen may cut their risk of the cancer returning or spreading. A common misperception is that remaining disease-free for five years means a “cure.” In reality, more than half of all recurrences happen five or more years after diagnosis. Therefore, continuous management of hormoneresponsive breast cancer to mini- mize the risk of recurrence may be necessary. “The important messageis that it may neverbe too late for women with breast cancer to do more to protect themselves against the ongoing risk of disease recurrence,” said Paul Goss, M.D., Ph.D., of the Massachusetts General Hospital in Boston, who led the MA-17 study. “These data reinforce the need for women diagnosed with breast cancer to go additional treatment? Am Ia candidate for Femara? What else can I do to reduce myrisk of a recurrence? Femarais approved for the adjuvant (following surgery) treatment of postmenopausal women with hormone receptor-positive 4 beg back to their doctors and continue to discuss ways to reduce their risk of recurrence.” Researchers have known for several years that starting Femara within three months of completing tamoxifen helped postmenopausal women reduce their risk of breast cancer coming back or spreading to other parts of the body. However, this new information showsthe potential benefit of treatment with this particular aromatase inhibitor for women who have beenoff tamoxifen, even for many years. Dr. Goss suggests that women who have finished tamoxifen begin a conversation about further reducing their risk of recurrence with their doctor by asking the following questions: Is it too late for me to start early-stage breast cancer. The benefits of Femara in clinical trials are based on 24 months of treatment. Further follow-up will be needed to determine long-term results, safety and efficacy. Femara is also approved for the extended adjuvant treatment of early stage breast cancer in postmenopausal women who are within three months of completion of five years of tamoxifen therapy. The benefits of Femara in clinical trials are based on 24 months of treatment. Further follow-up will be needed to determine long-term results, including side effects. In addition, Femara is ap- proved for the treatment of postmenopausal women with estrogen receptor-positive or estrogen receptor-unknown breast cancer that has spread to another part of the body (metastatic cancer). For more information about Femara, talk to your doctor and visit www.Femara.com or www.NovartisOncology.com. ee Note to Editors: Important Safety Information You should not take Femara if you are premenopausal. Your doctor should discuss the need for adequate birth control ifyou have the potential to become pregnant, ifyou are not sure ofyour postmenopausal status, or if you recently became postmenopausal. Femara is only indicated in postmenopausal women. Talk to your doctor ifyou’re allergic to Femara or any of its ingredients. You should not take Femara ifyou are pregnant as it may cause fetal harm. Some women reported fatigue and dizziness with Femara. Until you know how it affects you, use caution before driving or operating machinery. Some patients taking Femara had an increase in cholesterol. Additional follow-up is needed to determinethe risk of bone fracture associated with long-term use ofFemara. In the adjuvant setting, commonly reported side effects are generally mild to moderate. The most common side effects seen with Femara include hot flashes, joint pain, night sweats, weight gain, nausea, tiredness, other heart-related events and bone fractures. Other less commonly reported side effects include vaginal bleeding, blood clots, other cancers, osteoporosis, stroke, heart attack and endometrial cancer. In the extended adjuvant setting, commonly reported side effects are generally mild to moderate. Commonly reported side effects for Femara include hot flashes, fatigue, joint pain, headache, increase in sweating, swelling due to fluid retention, increase in cholesterol, dizziness, constipation, nausea, cardiovascular ischemic events, muscle pain, osteoporosis, arthritis and bonefracture. In the metastatic cancer setting, commonly reported side effects are generally mild to moderate and may include bone pain, hot flashes, back pain, nausea, joint pain, shortness of breath, tiredness, coughing, constipation, limb pain, chest pain and headache. Femara is a once-daily convenient prescription tablet. For additional safety information, please see the accompanying prescribing information. For more information about Femara visit online at www.femara.com orcall toll-free 1-866-44-FEMARA (1-866-443-3627). About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group’s businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http: / /wwww.novartis.com.